Benutzer: Gast  Login
Titel:

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.

Dokumenttyp:
Article; Case Reports; Journal Article; Research Support, Non-U.S. Gov't
Autor(en):
Bielack, S S; Cox, M C; Nathrath, M; Apel, K; Blattmann, C; Holl, T; Jenewein, R; Klenk, U; Klothaki, P; Müller-Abt, P; Ortega-Lawerenz, S; Reynolds, M; Scheer, M; Simon-Klingenstein, K; Stegmaier, S; Tupper, R; Vokuhl, C; von Kalle, T
Abstract:
BACKGROUND: The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent IFS to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib. PATIENT AND METHODS: A male infant born with a large congenital IFS of the tongue had the tumour surgically resected at age 4 days. Within 2 mont...     »
Zeitschriftentitel:
Ann Oncol
Jahr:
2019
Band / Volume:
30 Suppl 8
Seitenangaben Beitrag:
viii31-viii35
Volltext / DOI:
doi:10.1093/annonc/mdz382
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/32223937
Print-ISSN:
0923-7534
TUM Einrichtung:
Klinik und Poliklinik für Kinderheilkunde und Jugendmedizin
 BibTeX